Loading
A phase 3 trial of 64Cu-SAR-bisPSMA in prostate cancer, run by Clarity Pharmaceuticals Ltd, active and no longer recruiting.
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer is a phase 3 interventional study registered as NCT06970847 by Clarity Pharmaceuticals Ltd, with 220 participants enrolled, started 2025-05-16 and due to reach its primary completion in 2026-12-31. Interventions recorded: 64Cu-SAR-bisPSMA.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Clarity Pharmaceuticals, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Biochemical recurrence of prostate cancer, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/